PF-07224826 + fulvestrant

PF-07224826 + fulvestrant is an investigational oral combination therapy under evaluation for the treatment of hormone receptor–positive (HR+), HER2-negative locally advanced or metastatic breast cancer (mBC). PF-07224826 is administered orally and fulvestrant is administered according to standard protocols. PF-07224826 is developed by Pfizer and is currently being studied in combination with fulvestrant in populations with prior endocrine therapy or CDK4/6 inhibitor exposure. The exact mechanism of PF-07224826 is not explicitly stated in available sources, but based on clinical trial context, it is presumed to be a small molecule targeting mechanisms relevant to endocrine resistance pathways in breast cancer, potentially as a kinase inhibitor. Fulvestrant is a selective estrogen receptor degrader that promotes degradation of the estrogen receptor and blocks its activity[1][3][4][10].